The Week Ahead: Hom...
Health Care: Drugs
Puma Biotechnology Inc (PBYI: NYSE)
$37.36 2.58 | 7.42%
05/17/13 - 04:01 PM ET
Company Income Statement
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Sales | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Sales | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Operating Profit | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling, General, and Administrative Expenses | 24.81M | 9.32M | 15.98K | 16.84K |
| Research & Development | 49.64M | 826.37K | 0.00 | 0.00 |
| Operating Income before D & A (EBITDA) | -74.45M | -10.15M | -15.98K | -16.84K |
| Depreciation & Amortization | 265.00K | 10.70K | 0.00 | 0.00 |
| Interest Income | 98.00K | 3.78K | 0.00 | 0.00 |
| Other Income - Net | 0.00 | -80.00K | 0.00 | 0.00 |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -74.62M | -10.23M | -15.98K | -16.84K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 |
| Pre-Tax Income | -74.62M | -10.23M | -15.98K | -16.84K |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -74.35M | 0.00 | -15.98K | -16.84K |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -74.35M | 0.00 | -15.98K | -16.84K |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -74.35M | -10.23M | -15.98K | -16.84K |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-74.35M | 0.00 | -15.98K | -16.84K |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -74.35M | 0.00 | -15.98K | -16.84K |
| Basic EPS from Continuing Ops. | -3.42 | -1.32 | -0.01 | -0.01 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -3.42 | -1.32 | -0.01 | -0.01 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -3.42 | -1.32 | -0.01 | -0.01 |
| Basic Normalized Net Income/Share | -3.42 | n.a. | -0.01 | -0.01 |
| EPS fr Continuing Ops. | -3.42 | -1.32 | -0.01 | -0.01 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -3.42 | -1.32 | -0.01 | -0.01 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -3.42 | -1.32 | -0.01 | -0.01 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-3.42 | n.a. | -0.01 | -0.01 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with PBYI
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks With Big Insider Buy...
- ContributorStocks With Big Insider Buy...
Latest PBYI Headlines from TheStreet
- 3 Stocks Spiking on Big Volume 04.15.13 | 02:04 pm
- Top Insider Trades: NSH PBYI CONN EPHC 12.12.12 | 09:12 am
- Insiders Trading BLK FIRE SONS PBYI 10.23.12 | 09:10 am
- Insiders Trading NCT, PBYI, NAV, OPK 07.30.12 | 01:07 pm
- Insiders Trading FDO, PBYI, SUMR, ENTG 07.19.12 | 09:07 am
- Top Insider Trades: SPB PBYI GPK AXS 12.31.69 | 07:12 pm
Press Releases for PBYI
- Puma Biotechnology To Present At Cowen Healthcare Conference - Business Wire 02.26.13 | 08:02 am
- Puma Biotechnology Announces Agreement With FDA On Special Protocol Assessment For Phase III Trial Of PB272 (Neratinib) In HER2-Positive Metastatic Breast Cancer Patients - Business Wire 02.20.13 | 08:02 am
- Puma Biotechnology To Present At Leerink Swann Global Healthcare Conference - Business Wire 02.06.13 | 08:02 am
- Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data At CTRC-AACR San Antonio Breast Cancer Symposium - Business Wire 12.07.12 | 06:12 pm
- Puma Biotechnology Reports Third Quarter 2012 Financial Results - Business Wire 11.14.12 | 08:11 am
- Puma Biotechnology To Present At Lazard Healthcare Conference - Business Wire 11.07.12 | 08:11 am
- Puma Biotechnology Closes $138 Million Public Offering Of Common Stock - Business Wire 10.24.12 | 02:10 pm
- Puma Biotechnology Announces Underwriters’ Full Exercise Of Overallotment Option, Increasing Total Offering Size To $138 Million - Business Wire 10.22.12 | 08:10 am
- Puma Biotechnology Announces Upsizing And Pricing Of $120 Million Public Offering Of Common Stock - Business Wire 10.18.12 | 06:10 pm
- Puma Biotechnology To Present At UBS Global Life Sciences Conference - Business Wire 09.12.12 | 08:09 am
Partner Headlines for PBYI
- Analysts: CarMax Can Maintain Momentum and 3 New Opinions Investors Must Take a Peek At - Wall St. Cheat Sheet 04.02.13 | 11:04 am
- Moves in Smaller Health Care Stocks (ANAC, HALO, PBYI, QCOR) - Benzinga 03.23.13 | 11:03 am
